Empowering Health, Transforming Lives
We are focused on advancing cardiorenal innovation through integrated treatments that address unmet patient needs
Empowering Health, Transforming Lives
We are focused on advancing cardiorenal innovation through integrated treatments that address unmet patient needs
Patient-Driven
Cardiorenal Care
The scPharma Difference
Pioneering Care for the Heart and Kidney Connection
scPharmaceuticals is committed to revolutionizing cardiovascular and renal care through patient-centric approaches tailored to enhance outcomes, reduce burden, and increase quality of life.
Patient-Driven
Cardiorenal Care
The scPharma Difference
Pioneering Care for the Heart and Kidney Connection
scPharmaceuticals is committed to revolutionizing cardiovascular and renal care through patient-centric approaches tailored to enhance outcomes, reduce burden, and increase quality of life.
Pharmaceutical Development, Drug-Device Combinations,
and Product Commercialization Expertise
Integrated Expertise
Leading the Way in Value-Based Treatments for Heart Failure and Chronic Kidney Disease
Our focus on integrated, value-driven care positions us as a trusted leader in the industry, committed to improving patient lives and redefining healthcare standards.
Pharmaceutical Development, Drug-Device Combinations,
and Product Commercialization Expertise
Integrated Expertise
Leading the Way in Value-Based Treatments for Heart Failure and Chronic Kidney Disease
Our focus on integrated, value-driven care positions us as a trusted leader in the industry, committed to improving patient lives and redefining healthcare standards.
scPharmaceuticals
Cardiorenal Journey
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
-
2020
FUROSCIX Resubmission
- FUROSCIX NDA Resubmission
- Receives Complete Response Letter from FDA for FUROSCIX®
-
2021
FREEDOM-HF Results
- Positive Top-Line Results from FREEDOM-HF Study
-
2022
FUROSCIX Approval and Financing
- Resubmission of FUROSCIX® (furosemide injection) New Drug Application
- Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
- FDA Approval of FUROSCIX® (furosemide injection)
- $100 Million Debt Financing Agreement with Oaktree
-
2023
FUROSCIX Launch
- Launch and Commercial Availability of FUROSCIX® (furosemide injection)
- Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion
-
2024
Indication Expansion Progress
- First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
- Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease
- Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
- FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
- Financings Totaling Up to $125 Million with Perceptive Advisors
-
2025
Continued FUROSCIX Growth
- Chronic Kidney Disease indication FDA approved on March 6, 2025
Investing in Our
Shared Future
Discover the latest insights into our company’s growth and future vision. Stay informed about the strategic decisions shaping our path forward.
Quick IR Links
Quick IR Links
Newsroom
March 19, 2025
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million , and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include...
March 12, 2025
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass. , March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric...
March 06, 2025
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025...
February 26, 2025
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
BURLINGTON, Mass. , Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker , President and Chief Executive Officer,...
Empowering Heros on
Career Journeys
scPharmaceuticals is committed to revolutionizing cardiovascular and renal care through patient-centric approaches tailored to enhance outcomes, reduce burden, and increase quality of life.
